RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research

被引：207

作者：

Lapchak, Paul A. ^{[1
]}

Zhang, John H. ^{[2
]}

Noble-Haeusslein, Linda J. ^{[3
,4
]}

机构：

[1] Cedars Sinai Med Ctr, Dept Neurol, Los Angeles, CA 90048 USA

[2] Loma Linda Univ, Sch Med, Dept Neurosurg Anesthesiol Neurol & Physiol & Pha, Loma Linda, CA 92350 USA

[3] Univ Calif San Francisco, Dept Neurol Surg Phys Therapy & Rehabil Sci, San Francisco, CA 94143 USA

[4] Univ Calif San Francisco, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94143 USA

来源：

TRANSLATIONAL STROKE RESEARCH | 2013年 / 4卷 / 03期

关键词：

Translational; Brain; Stroke; Hemorrhage; SAH; ICH; Clinical Trial; NIHSS; STAIR; STEPS; RIGOR; STROKE STATISTICS-2010 UPDATE; TISSUE-PLASMINOGEN ACTIVATOR; ACUTE ISCHEMIC-STROKE; CEREBRAL-ISCHEMIA; HEART-DISEASE; TREAT STROKE; THERAPY; NEUROPROTECTION; RECOMMENDATIONS; NXY-059;

D O I：

10.1007/s12975-012-0209-2

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Stroke continues to be a serious and significant health problem in the USA and worldwide. This article will emphasize the need for good laboratory practices, transparent scientific reporting, and the use of translational research models representative of the disease state to develop effective treatments. This will allow for the testing and development of new innovative strategies so that efficacious therapies can be developed to treat ischemic and hemorrhagic stroke. This article recommends guidelines for effective translational research, most importantly, the need for study blinding, study group randomization, power analysis, accurate statistical analysis, and a conflict of interest statement. Additional guidelines to ensure reproducibility of results and confirmation of efficacy in multiple species are discussed.

引用

页码：279 / 285

页数：7

共 53 条

[1] Stroke Treatment Academic Industry Roundtable (STAIR) Recommendations for Maximizing the Use of Intravenous Thrombolytics and Expanding Treatment Options With Intra-arterial and Neuroprotective Therapies [J].

Albers, Gregory W. ;

Goldstein, Larry B. ;

Hess, David C. ;

Wechsler, Lawrence R. ;

Furie, Karen L. ;

Gorelick, Philip B. ;

Hurn, Patty ;

Liebeskind, David S. ;

Nogueira, Raul G. ;

Saver, Jeffrey L. .

STROKE, 2011, 42 (09) :2645-2650

[2] The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome [J].

Baird, TA ;

Parsons, MW ;

Barber, PA ;

Butcher, KS ;

Desmond, PM ;

Tress, BM ;

Colman, PG ;

Jerums, G ;

Chambers, BR ;

Davis, SM .

JOURNAL OF CLINICAL NEUROSCIENCE, 2002, 9 (06) :618-626

[3] Effects of NXY-059 in experimental stroke: an individual animal meta-analysis [J].

Bath, P. M. W. ;

Gray, L. J. ;

Bath, A. J. G. ;

Buchan, A. ;

Miyata, T. ;

Green, A. R. .

BRITISH JOURNAL OF PHARMACOLOGY, 2009, 157 (07) :1157-1171

[4] Recent advances in the management of acute intracerebral hemorrhage [J].

Bernstein R.A. ;

Del-Signore M. .

Current Neurology and Neuroscience Reports, 2005, 5 (6) :483-487

[5] A Model of Cost-effectiveness of Tissue Plasminogen Activator in Patient Subgroups 3 to 4.5 Hours After Onset of Acute Ischemic Stroke [J].

Boudreau, Denise M. ;

Guzauskas, Greg ;

Villa, Kathleen F. ;

Fagan, Susan C. ;

Veenstra, David L. .

ANNALS OF EMERGENCY MEDICINE, 2013, 61 (01) :46-55

[6]

BRAMWELL B, 1886, EDINBURGH MED J, V32, P101

[7] Neurorestorative Treatment of Stroke: Cell and Pharmacological Approaches [J].

Chen J. ;

Chopp M. .

NeuroRX, 2006, 3 (4) :466-473

[8] Nonhuman Primate Models of Stroke for Translational Neuroprotection Research [J].

Cook, Douglas J. ;

Tymianski, Michael .

NEUROTHERAPEUTICS, 2012, 9 (02) :371-379

[9]

Dechambre A, 1866, DICT ENCY SCI MED, V18

[10] Trends in Thrombolytic Use for Ischemic Stroke in the United States [J].

Fang, Margaret C. ;

Cutler, David M. ;

Rosen, Allison B. .

JOURNAL OF HOSPITAL MEDICINE, 2010, 5 (07) :406-409

← 1 2 3 4 5 6 →